Monoclonal antibody reduces asthma attacks in urban youth

A National Institutes of Health clinical trial has found that a monoclonal antibody, mepolizumab, decreased asthma attacks by 27% in Black and Hispanic children and adolescents who have a form of severe asthma, are prone to asthma attacks and live in low-income urban neighborhoods. This population has been underrepresented in previous clinical trials of asthma therapeutics. The findings were published today in the journal The Lancet.